Investegate |Indivior PLC Announcements | Indivior PLC: Indivior Raises FY 2021 Guidance investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
New Oral Medication Offers Established Antipsychotic Efficacy of Olanzapine With Less Weight Gain Commercial Launch Planned for Fourth Quarter 2021 Company to Host Investor
/PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved LYBALVI™ (olanzapine and samidorphan).
Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month
New Outcomes Research in Patients With Schizophrenia or Bipolar I Disorder to be Presented
Published 05-04-21
Submitted by Alkermes
DUBLIN, May 4, 2021 /CSRwire/ Alkermes plc (Nasdaq: ALKS) recently announced plans to present clinical data and outcomes research from its psychiatry portfolio at three scientific conferences during Mental Health Awareness Month in May. The meetings, all held virtually, include:
American Psychiatric Association (APA) Annual Meeting, May 1-3;
International Society for Bipolar Disorders (ISBD) Annual Conference, May 13-15;
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, May 17-20.
5 - Adjusted (Adj.) basis excludes the impact of exceptional items as referenced in Notes 3 and 4. Comment by Mark Crossley, CEO of Indivior PLC We have seen an encouraging start in FY 2021 with growth in net revenue, operating profit and cash from execution against our strategic priorities. Despite the ongoing impacts of COVID-19, SUBLOCADE® (buprenorphine extended-release) injection achieved solid net revenue growth both on a sequential and year-over-year basis, and we expanded our Organized Health Systems (OHS) platform to build the foundation for future growth. Looking ahead, we are seeing healthcare restrictions in the US begin to ease from the rapid pace of COVID-19 vaccinations, which supports our expectation of increased in-person interactions with healthcare practitioners in the second half of the year. As such, we are reiterating our FY 2021 base case guidance.